LeMaitre Vascular (LMAT) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales grew 16% year-over-year to $54.8M, driven by strong performance in grafts, patches, carotid shunts, higher selling prices, and expanded direct sales force, with APAC and EMEA leading regional growth.

• EPS rose 49% year-over-year to $0.49, reflecting pricing, operational execution, and margin expansion.

• Biologics accounted for 52% of Q3 2024 sales, and direct-to-hospital sales represented 95% of total net sales.

• The company holds #1 or #2 share in 9 of 12 niche markets, serving over 4,950 hospital accounts globally, and maintains a strong direct sales force of 146 reps as of 9/30/24, targeting 155-160 by year-end.

• Product portfolio expansion is driven by accretive acquisitions, organic growth, and price increases.

Financial highlights

• Q3 2024 gross margin reached 67.8%, up 280 basis points year-over-year, driven by higher ASPs and manufacturing efficiencies.

• Q3 2024 operating income was $13.1M, up 43% year-over-year, with an operating margin of 24%.

• Net income for Q3 2024 was $11.1M, up 49% year-over-year; EBITDA for Q3 2024 was $15.8M, a 39% increase.

• Cash and investments totaled $124M at quarter-end, with no long-term debt.

• Dividend per share increased to $0.16 in Q3 2024, marking 13 consecutive years of dividend growth.

Outlook and guidance

• Q4 2024 guidance: sales growth of 14% (reported and organic), gross margin of 68%, operating income of $13.3M (up 30%), and EPS of $0.49 (up 30%).

• Full-year 2024 guidance: sales midpoint $220M (+14%), gross margin 68.3%, operating income $52.7M (+44%), EPS $1.94 (+44%).

• Targeting 155-160 sales reps by year-end, with further expansion planned, especially in Europe.

• Management expects continued growth through direct sales expansion, new product launches, and acquisitions.